Stockscreener 앱 받기
18.95
4.35%
0.79
시장 영업 전:
18.87
-0.08
-0.42%
전일 마감가:
$18.16
열려 있는:
$18.16
하루 거래량:
8.05M
Relative Volume:
0.68
시가총액:
$1.85B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-7.0446
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
+4.87%
1개월 성능:
+19.11%
6개월 성능:
-81.28%
1년 성능:
-85.97%
1일 변동 폭
$17.95
$19.61
1주일 범위
$17.79
$19.61
52주 변동 폭
$10.41
$138.81
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.95 | 1.90B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
What recovery options are there for Sarepta Therapeutics Inc.July 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Behavioral Patterns of SRPT and Institutional Flows - news.stocktradersdaily.com
Long term hold vs stop loss in Sarepta Therapeutics Inc.Trend Reversal & Stepwise Trade Execution Plans - Newser
Technical Reactions to SRPT Trends in Macro Strategies - news.stocktradersdaily.com
Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results - Insider Monkey
Sarepta Therapeutics Inc. stock prediction for this weekJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
Can Sarepta Therapeutics Inc. hit a new high this monthQuarterly Profit Report & AI Powered Market Entry Ideas - Newser
Understanding Momentum Shifts in (SRPT) - news.stocktradersdaily.com
Promising Small Cap Stocks To Follow Now – September 1st - Defense World
What institutional flow reveals about Sarepta Therapeutics Inc.2025 Market Overview & Weekly High Potential Stock Alerts - Newser
Understanding the Setup: (SRPT) and Scalable Risk - news.stocktradersdaily.com
(SRPT) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Technical signs of recovery in Sarepta Therapeutics Inc.Market Weekly Review & Safe Capital Growth Trade Ideas - Newser
Top 20 Most-Searched Stock Tickers on Benzinga Pro in AugustApple (NASDAQ:AAPL) - Benzinga
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. showing signs of accumulationChart Signals & High Accuracy Swing Trade Signals - Newser
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Key resistance and support levels for Sarepta Therapeutics Inc.Earnings Miss & Stock Portfolio Risk Management - Newser
Does Sarepta Therapeutics Inc. fit your quant trading model2025 Volume Leaders & Intraday High Probability Setup Alerts - Newser
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
SRPT's Index Shift: Implications for Value and Momentum Investors - AInvest
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to S&P 600 Health Care - MarketScreener
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to S&P 600 - MarketScreener
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from S&P 400Biotechnology - MarketScreener
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from S&P 400 Health Care - MarketScreener
Sarepta Therapeutics Restructures Amid ELEVIDYS Challenges - TipRanks
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
Liquidity Mapping Around (SRPT) Price Events - news.stocktradersdaily.com
What MACD and RSI say about Sarepta Therapeutics Inc.2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Real time social sentiment graph for Sarepta Therapeutics Inc.Portfolio Value Summary & Long-Term Growth Plans - Newser
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(SRPT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How (SRPT) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
(SRPT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. reversing from oversold territoryAnalyst Downgrade & Daily Volume Surge Signals - Newser
Discipline and Rules-Based Execution in SRPT Response - news.stocktradersdaily.com
What Fibonacci levels say about Sarepta Therapeutics Inc. reboundMarket Risk Analysis & Pattern Based Trade Signal System - Newser
Has Sarepta Therapeutics Inc. formed a bullish divergenceWeekly Risk Report & AI Based Buy and Sell Signals - Newser
Why (SRPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Will Sarepta Therapeutics Inc. benefit from macro trendsMarket Performance Summary & Capital Protection Trade Alerts - Newser
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Sarepta Therapeutics Inc. stock outlook for YEARJuly 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Is now a turning point for Sarepta Therapeutics Inc.2025 Winners & Losers & High Accuracy Trade Alerts - Newser
Sarepta Therapeutics Completes Convertible Notes Exchange - TipRanks
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.14%
1.34%
자본화:
|
볼륨(24시간):